Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Johnson and Johnson
Federal Trade Commission
AstraZeneca
Covington
US Department of Justice
Citi
Boehringer Ingelheim

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,216,167

« Back to Dashboard

Which drugs does patent 9,216,167 protect, and when does it expire?

Patent 9,216,167 protects ACULAR LS and is included in one NDA.

This patent has four patent family members in three countries.
Summary for Patent: 9,216,167
Title:Ketorolac tromethamine compositions for treating or preventing ocular pain
Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
Inventor(s): Muller; Christopher A. (Foothill Ranch, CA), Cheetham; Janet K. (Laguna Niguel, CA), Kuan; Teresa H. (Placentia, CA), Power; David F. (Trabuco Canyon, CA)
Assignee: Allergan Sales, LLC. (Irvine, CA)
Application Number:14/533,798
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,216,167

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan ACULAR LS ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 021528-001 May 30, 2003 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,216,167

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,946,281 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Try a Free Trial
8,377,982 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Try a Free Trial
8,008,338 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Try a Free Trial
8,906,950 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,216,167

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2468664 ➤ Try a Free Trial
Canada 2967362 ➤ Try a Free Trial
European Patent Office 3217937 ➤ Try a Free Trial
World Intellectual Property Organization (WIPO) 2016077726 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Baxter
Moodys
Dow
Accenture
Fuji
Covington
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.